Annovera is designed for 21 days of continuous use, followed by a seven-day ring-free interval, during which the ring is removed, washed, and stored. Unlike other products, the same ring is used for subsequent cycles for an entire year (13 cycles total).
Data from the latest release of the National Survey of Family Growth supports that the contraception coverage mandate of the Affordable Care Act has resulted in a decrease in the incidence of unintended pregnancy, particularly among women with government coverage.
Drug delivery platform will release medication for monthly dosing
August 30, 2019
Although lowering side effects plays an important role in oral contraceptive compliance, one of the biggest challenges for patients is adhering to the daily schedule of the pill. Forgetting one to three pills per cycle is a frequent problem among 15-51% of users, particularly among adolescents. Lyndra Therapeutics has received a $13 million grant from the Bill & Melinda Gates Foundation and is setting out to remove the daily pill compliance challenge. The company is in early development of a monthly oral contraceptive to provide women with a discreet, noninvasive, reversible contraception option.
In this retrospective cohort study of 279 women undergoing postpartum partial salpingectomy after vaginal delivery, the mean operative time for women with a BMI ≥ 30 kg/m2 was only 5.5 minutes longer than the time for women with a BMI < 30 kg/m2.
Despite guidance stating that a patient should be offered the option to begin her chosen long-acting reversible contraception birth control method at the time of the office visit rather than waiting for her next period or returning for another appointment, just 29% of clinicians say they provide same-day placement.
Family planning providers should develop ways to provide contraceptives to patients in one visit (known as Quick Start) for all methods, according to the Family Planning National Training Center’s Contraceptive Access Change Package. New research indicates that while most public-sector and private providers consider Quick Start for combined hormonal contraceptives and depot medroxyprogesterone acetate (DMPA) safe for use among adolescents, fewer private providers utilize the technique.
In 2002, just 2.4% of U.S. women using birth control were using long-acting reversible contraceptive (LARC) methods, such as the intrauterine device or the contraceptive implant. By 2014, about 14% of women using birth control reported LARC use.